This article is more than 5 years old. Information may no longer be current.
KDIGO releases update on guidelines for the management of hepatitis C
Click Here to Manage Email Alerts
Kidney Disease: Improving Global Outcomes, also known as KDIGO, has released an update to its Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in Chronic Kidney Disease guidelines, replacing the version first published by the group in 2008.
The update has been under development for the past 2 years under the leadership of Michel Jadoul, MD, of Belgium, and Paul Martin, MD, of the United States. A work group consisting of nephrologists, hepatologists, infectious disease experts and transplant specialists crafted the recommendations with the assistance of an independent professional evidence review team from Brown University School of Public Health, KDIGO said in a press release.
“The complete update of the previous guideline was necessary since the hepatitis C treatment landscape has changed dramatically in the last 5 years,” Jadoul said in the release.
The updated guideline includes the latest recommendations on: detection and evaluation of hepatitis C (HCV) in CKD; kidney and liver function testing in patients with CKD and HCV; therapeutic agents for the treatment of HCV in dialysis and non-dialysis patients, including kidney transplant recipients; prevention of HCV transmissions in hemodialysis and tracking of new infections; evaluation and management of kidney transplant candidates with HCV infections; and diagnosis and treatment of kidney diseases associated with HCV infections.
Prior to the publication of this guideline, the document went through two periods of public review.
Reference:
www.kdigo.org